In the current "tan stock price forecast", macroeconomic tailwinds, including U.S. tax credits for solar projects, are boosting investor confidence. The ETF’s weighted holdings in top solar companies may push a near-term target of $65. It seems insiders own a significant proportion of Tan Chong Motor Holdings Berhad. It has a market capitalization of just RM525m, and insiders have RM152m worth of shares in their own names. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently. Daiichi Sankyo is a global leader in antibody-drug conjugate drugs for cancer treatment. Its flagship drug, Enhertu, is a HER2-targeting ADC that has become a transformative treatment for some types of HER2-expressing cancers, and Daiichi has a pipeline of other ADC candidates for other cancers. We view shares as modestly cheap, based on our cautious assessment of currently available clinical data, but we also expect share price volatility since its prospects are so reliant on future readouts. In September 2024, a disappointing readout for Dato-DXd (TROP2-targeting ADC) in second-line lung cancer put a dent in Daiichi’s near-term growth prospects, but we think it should still enjoy strong growth, thanks to Enhertu. The "tan stock price forecast" incorporates geopolitical analysis, with stable U.S.–China trade relations reducing supply chain risks in clean energy manufacturing.